B-intervention	0	4	Risk
I-intervention	4	5	-
I-intervention	5	12	adapted
I-intervention	13	21	targeted
I-intervention	22	36	intraoperative
I-intervention	37	49	radiotherapy
O	50	56	versus
B-control	57	62	whole
I-control	62	63	-
I-control	63	69	breast
I-control	70	82	radiotherapy
O	83	86	for
O	87	93	breast
O	94	100	cancer
O	100	101	:
O	102	103	5
O	103	104	-
O	104	108	year
O	109	116	results
O	117	120	for
O	121	126	local
O	127	134	control
O	135	138	and
O	139	146	overall
O	147	155	survival
O	156	160	from
O	161	164	the
O	165	171	TARGIT
O	171	172	-
O	172	173	A
O	174	184	randomised
O	185	190	trial
O	190	191	.

O	192	195	The
O	196	202	TARGIT
O	202	203	-
O	203	204	A
O	205	210	trial
O	211	219	compared
O	220	224	risk
O	224	225	-
O	225	232	adapted
O	233	245	radiotherapy
O	246	251	using
O	252	258	single
O	258	259	-
O	259	263	dose
O	264	272	targeted
O	273	287	intraoperative
O	288	300	radiotherapy
O	301	302	(
O	302	308	TARGIT
O	308	309	)
O	310	316	versus
O	317	329	fractionated
O	330	338	external
O	339	343	beam
O	344	356	radiotherapy
O	357	358	(
O	358	362	EBRT
O	362	363	)
O	364	367	for
O	368	374	breast
O	375	381	cancer
O	381	382	.

O	383	385	We
O	386	392	report
O	393	394	5
O	394	395	-
O	395	399	year
O	400	407	results
O	408	411	for
O	412	417	local
O	418	428	recurrence
O	429	432	and
O	433	436	the
O	437	442	first
O	443	451	analysis
O	452	454	of
O	455	462	overall
O	463	471	survival
O	471	472	.

O	473	479	TARGIT
O	479	480	-
O	480	481	A
O	482	485	was
O	486	487	a
O	488	498	randomised
O	498	499	,
O	500	503	non
O	503	504	-
O	504	515	inferiority
O	516	521	trial
O	521	522	.

O	523	528	Women
O	529	533	aged
B-age	534	536	45
I-age	537	542	years
I-age	543	546	and
I-age	547	552	older
O	553	557	with
O	558	566	invasive
O	567	573	ductal
O	574	583	carcinoma
O	584	588	were
O	589	597	enrolled
O	598	601	and
O	602	610	randomly
O	611	619	assigned
O	620	622	in
O	623	624	a
O	625	626	1
O	626	627	:
O	627	628	1
O	629	634	ratio
O	635	637	to
O	638	645	receive
O	646	652	TARGIT
O	653	655	or
O	656	661	whole
O	661	662	-
O	662	668	breast
O	669	673	EBRT
O	673	674	,
O	675	679	with
O	680	686	blocks
O	687	697	stratified
O	698	700	by
O	701	707	centre
O	708	711	and
O	712	714	by
O	715	721	timing
O	722	724	of
O	725	733	delivery
O	734	736	of
O	737	745	targeted
O	746	760	intraoperative
O	761	773	radiotherapy
O	773	774	:
O	775	788	randomisation
O	789	797	occurred
O	798	804	either
O	805	811	before
O	812	822	lumpectomy
O	823	824	(
O	824	836	prepathology
O	837	844	stratum
O	844	845	,
O	846	852	TARGIT
O	853	863	concurrent
O	864	868	with
O	869	879	lumpectomy
O	879	880	)
O	881	883	or
O	884	889	after
O	890	900	lumpectomy
O	901	902	(
O	902	915	postpathology
O	916	923	stratum
O	923	924	,
O	925	931	TARGIT
O	932	937	given
O	938	950	subsequently
O	951	953	by
O	954	963	reopening
O	964	967	the
O	968	973	wound
O	973	974	)
O	974	975	.

O	976	984	Patients
O	985	987	in
O	988	991	the
O	992	998	TARGIT
O	999	1004	group
O	1005	1013	received
O	1014	1026	supplemental
O	1027	1031	EBRT
O	1032	1033	(
O	1033	1042	excluding
O	1043	1044	a
O	1045	1050	boost
O	1050	1051	)
O	1052	1054	if
O	1055	1065	unforeseen
O	1066	1073	adverse
O	1074	1082	features
O	1083	1087	were
O	1088	1096	detected
O	1097	1099	on
O	1100	1105	final
O	1106	1115	pathology
O	1115	1116	,
O	1117	1121	thus
O	1122	1134	radiotherapy
O	1135	1138	was
O	1139	1143	risk
O	1143	1144	-
O	1144	1151	adapted
O	1151	1152	.

O	1153	1156	The
O	1157	1164	primary
O	1165	1172	outcome
O	1173	1176	was
B-outcome-Measure	1177	1185	absolute
I-outcome-Measure	1186	1196	difference
I-outcome-Measure	1197	1199	in
I-outcome-Measure	1200	1205	local
I-outcome-Measure	1206	1216	recurrence
I-outcome-Measure	1217	1219	in
I-outcome-Measure	1220	1223	the
I-outcome-Measure	1224	1233	conserved
I-outcome-Measure	1234	1240	breast
O	1240	1241	,
O	1242	1246	with
O	1247	1248	a
O	1249	1261	prespecified
O	1262	1265	non
O	1265	1266	-
O	1266	1277	inferiority
O	1278	1284	margin
O	1285	1287	of
O	1288	1289	2
O	1289	1290	·
O	1290	1291	5
O	1291	1292	%
O	1293	1295	at
O	1296	1297	5
O	1298	1303	years
O	1303	1304	;
O	1305	1317	prespecified
O	1318	1326	analyses
O	1327	1335	included
O	1336	1344	outcomes
O	1345	1347	as
O	1348	1351	per
O	1352	1358	timing
O	1359	1361	of
O	1362	1375	randomisation
O	1376	1378	in
O	1379	1387	relation
O	1388	1390	to
O	1391	1401	lumpectomy
O	1401	1402	.

O	1403	1412	Secondary
O	1413	1421	outcomes
O	1422	1430	included
B-outcome-Measure	1431	1444	complications
O	1445	1448	and
B-outcome-Measure	1449	1458	mortality
O	1458	1459	.

O	1460	1464	This
O	1465	1470	study
O	1471	1473	is
O	1474	1484	registered
O	1485	1489	with
O	1490	1504	ClinicalTrials
O	1504	1505	.
O	1505	1508	gov
O	1508	1509	,
O	1510	1516	number
O	1517	1528	NCT00983684
O	1528	1529	.

O	1530	1538	Patients
O	1539	1543	were
O	1544	1552	enrolled
O	1553	1555	at
O	1556	1558	33
O	1559	1566	centres
O	1567	1569	in
O	1570	1572	11
O	1573	1582	countries
O	1582	1583	,
O	1584	1591	between
O	1592	1597	March
O	1598	1600	24
O	1600	1601	,
O	1602	1606	2000
O	1606	1607	,
O	1608	1611	and
O	1612	1616	June
O	1617	1619	25
O	1619	1620	,
O	1621	1625	2012
O	1625	1626	.

B-intervention-participants	1627	1631	1721
O	1632	1640	patients
O	1641	1645	were
O	1646	1656	randomised
O	1657	1659	to
O	1660	1666	TARGIT
O	1667	1670	and
B-control-participants	1671	1675	1730
O	1676	1678	to
O	1679	1683	EBRT
O	1683	1684	.

O	1685	1697	Supplemental
O	1698	1702	EBRT
O	1703	1708	after
O	1709	1715	TARGIT
O	1716	1719	was
O	1720	1729	necessary
O	1730	1732	in
O	1733	1735	15
O	1735	1736	·
O	1736	1737	2
O	1737	1738	%
O	1739	1740	[
O	1740	1743	239
O	1744	1746	of
O	1747	1751	1571
O	1751	1752	]
O	1753	1755	of
O	1756	1764	patients
O	1765	1768	who
O	1769	1777	received
O	1778	1784	TARGIT
O	1785	1786	(
O	1786	1788	21
O	1788	1789	·
O	1789	1790	6
O	1790	1791	%
O	1792	1804	prepathology
O	1804	1805	,
O	1806	1807	3
O	1807	1808	·
O	1808	1809	6
O	1809	1810	%
O	1811	1824	postpathology
O	1824	1825	)
O	1825	1826	.

B-total-participants	1827	1831	3451
O	1832	1840	patients
O	1841	1844	had
O	1845	1846	a
O	1847	1853	median
O	1854	1860	follow
O	1860	1861	-
O	1861	1863	up
O	1864	1866	of
O	1867	1868	2
O	1869	1874	years
O	1875	1878	and
O	1879	1880	5
O	1881	1887	months
O	1888	1889	(
O	1889	1892	IQR
O	1893	1895	12
O	1895	1896	-
O	1896	1898	52
O	1899	1905	months
O	1905	1906	)
O	1906	1907	,
B-total-participants	1908	1912	2020
O	1913	1915	of
O	1916	1917	4
O	1918	1923	years
O	1923	1924	,
O	1925	1928	and
B-total-participants	1929	1933	1222
O	1934	1936	of
O	1937	1938	5
O	1939	1944	years
O	1944	1945	.

O	1946	1949	The
B-outcome	1950	1951	5
I-outcome	1951	1952	-
I-outcome	1952	1956	year
I-outcome	1957	1961	risk
I-outcome	1962	1965	for
I-outcome	1966	1971	local
I-outcome	1972	1982	recurrence
O	1983	1985	in
O	1986	1989	the
O	1990	1999	conserved
O	2000	2006	breast
O	2007	2010	was
B-iv-bin-percent	2011	2012	3
I-iv-bin-percent	2012	2013	·
I-iv-bin-percent	2013	2014	3
I-iv-bin-percent	2014	2015	%
O	2016	2017	(
O	2017	2019	95
O	2019	2020	%
O	2021	2023	CI
O	2024	2025	2
O	2025	2026	·
O	2026	2027	1
O	2027	2028	-
O	2028	2029	5
O	2029	2030	·
O	2030	2031	1
O	2031	2032	)
O	2033	2036	for
O	2037	2043	TARGIT
O	2044	2050	versus
B-cv-bin-percent	2051	2052	1
I-cv-bin-percent	2052	2053	·
I-cv-bin-percent	2053	2054	3
I-cv-bin-percent	2054	2055	%
O	2056	2057	(
O	2057	2058	0
O	2058	2059	·
O	2059	2060	7
O	2060	2061	-
O	2061	2062	2
O	2062	2063	·
O	2063	2064	5
O	2064	2065	)
O	2066	2069	for
O	2070	2074	EBRT
O	2075	2076	(
O	2076	2077	p
O	2077	2078	=
O	2078	2079	0
O	2079	2080	·
O	2080	2083	042
O	2083	2084	)
O	2084	2085	.

B-outcome	2086	2092	TARGIT
I-outcome	2093	2105	concurrently
I-outcome	2106	2110	with
I-outcome	2111	2121	lumpectomy
I-outcome	2122	2123	(
I-outcome	2123	2135	prepathology
O	2135	2136	,
O	2137	2138	n
O	2138	2139	=
O	2139	2143	2298
O	2143	2144	)
O	2145	2148	had
O	2149	2153	much
O	2154	2157	the
O	2158	2162	same
O	2163	2170	results
O	2171	2173	as
O	2174	2178	EBRT
O	2178	2179	:
B-iv-bin-percent	2180	2181	2
I-iv-bin-percent	2181	2182	·
I-iv-bin-percent	2182	2183	1
I-iv-bin-percent	2183	2184	%
O	2185	2186	(
O	2186	2187	1
O	2187	2188	·
O	2188	2189	1
O	2189	2190	-
O	2190	2191	4
O	2191	2192	·
O	2192	2193	2
O	2193	2194	)
O	2195	2201	versus
B-cv-bin-percent	2202	2203	1
I-cv-bin-percent	2203	2204	·
I-cv-bin-percent	2204	2205	1
I-cv-bin-percent	2205	2206	%
O	2207	2208	(
O	2208	2209	0
O	2209	2210	·
O	2210	2211	5
O	2211	2212	-
O	2212	2213	2
O	2213	2214	·
O	2214	2215	5
O	2215	2216	;
O	2217	2218	p
O	2218	2219	=
O	2219	2220	0
O	2220	2221	·
O	2221	2223	31
O	2223	2224	)
O	2224	2225	.

O	2226	2230	With
B-outcome	2231	2238	delayed
I-outcome	2239	2245	TARGIT
I-outcome	2246	2247	(
I-outcome	2247	2260	postpathology
O	2260	2261	,
O	2262	2263	n
O	2263	2264	=
O	2264	2268	1153
O	2268	2269	)
O	2270	2273	the
O	2274	2281	between
O	2281	2282	-
O	2282	2287	group
O	2288	2298	difference
O	2299	2302	was
O	2303	2309	larger
O	2310	2314	than
B-iv-bin-percent	2315	2316	2
I-iv-bin-percent	2316	2317	·
I-iv-bin-percent	2317	2318	5
I-iv-bin-percent	2318	2319	%
O	2320	2321	(
O	2321	2327	TARGIT
O	2328	2329	5
O	2329	2330	·
O	2330	2331	4
O	2331	2332	%
O	2333	2334	[
O	2334	2335	3
O	2335	2336	·
O	2336	2337	0
O	2337	2338	-
O	2338	2339	9
O	2339	2340	·
O	2340	2341	7
O	2341	2342	]
O	2343	2345	vs
O	2346	2350	EBRT
B-cv-bin-percent	2351	2352	1
I-cv-bin-percent	2352	2353	·
I-cv-bin-percent	2353	2354	7
I-cv-bin-percent	2354	2355	%
O	2356	2357	[
O	2357	2358	0
O	2358	2359	·
O	2359	2360	6
O	2360	2361	-
O	2361	2362	4
O	2362	2363	·
O	2363	2364	9
O	2364	2365	]
O	2365	2366	;
O	2367	2368	p
O	2368	2369	=
O	2369	2370	0
O	2370	2371	·
O	2371	2374	069
O	2374	2375	)
O	2375	2376	.

O	2377	2384	Overall
O	2384	2385	,
B-outcome	2386	2392	breast
I-outcome	2393	2399	cancer
I-outcome	2400	2409	mortality
O	2410	2413	was
O	2414	2418	much
O	2419	2422	the
O	2423	2427	same
O	2428	2435	between
O	2436	2442	groups
O	2443	2444	(
B-iv-bin-percent	2444	2445	2
I-iv-bin-percent	2445	2446	·
I-iv-bin-percent	2446	2447	6
I-iv-bin-percent	2447	2448	%
O	2449	2450	[
O	2450	2451	1
O	2451	2452	·
O	2452	2453	5
O	2453	2454	-
O	2454	2455	4
O	2455	2456	·
O	2456	2457	3
O	2457	2458	]
O	2459	2462	for
O	2463	2469	TARGIT
O	2470	2472	vs
B-cv-bin-percent	2473	2474	1
I-cv-bin-percent	2474	2475	·
I-cv-bin-percent	2475	2476	9
I-cv-bin-percent	2476	2477	%
O	2478	2479	[
O	2479	2480	1
O	2480	2481	·
O	2481	2482	1
O	2482	2483	-
O	2483	2484	3
O	2484	2485	·
O	2485	2486	2
O	2486	2487	]
O	2488	2491	for
O	2492	2496	EBRT
O	2496	2497	;
O	2498	2499	p
O	2499	2500	=
O	2500	2501	0
O	2501	2502	·
O	2502	2504	56
O	2504	2505	)
O	2506	2509	but
O	2510	2515	there
O	2516	2520	were
O	2521	2534	significantly
O	2535	2540	fewer
B-outcome	2541	2544	non
I-outcome	2544	2545	-
I-outcome	2545	2551	breast
I-outcome	2551	2552	-
I-outcome	2552	2558	cancer
I-outcome	2559	2565	deaths
O	2566	2570	with
O	2571	2577	TARGIT
O	2578	2579	(
B-iv-bin-percent	2579	2580	1
I-iv-bin-percent	2580	2581	·
I-iv-bin-percent	2581	2582	4
I-iv-bin-percent	2582	2583	%
O	2584	2585	[
O	2585	2586	0
O	2586	2587	·
O	2587	2588	8
O	2588	2589	-
O	2589	2590	2
O	2590	2591	·
O	2591	2592	5
O	2592	2593	]
O	2594	2596	vs
B-cv-bin-percent	2597	2598	3
I-cv-bin-percent	2598	2599	·
I-cv-bin-percent	2599	2600	5
I-cv-bin-percent	2600	2601	%
O	2602	2603	[
O	2603	2604	2
O	2604	2605	·
O	2605	2606	3
O	2606	2607	-
O	2607	2608	5
O	2608	2609	·
O	2609	2610	2
O	2610	2611	]
O	2611	2612	;
O	2613	2614	p
O	2614	2615	=
O	2615	2616	0
O	2616	2617	·
O	2617	2621	0086
O	2621	2622	)
O	2622	2623	,
O	2624	2636	attributable
O	2637	2639	to
O	2640	2645	fewer
O	2646	2652	deaths
O	2653	2657	from
O	2658	2672	cardiovascular
O	2673	2679	causes
O	2680	2683	and
O	2684	2689	other
O	2690	2697	cancers
O	2697	2698	.

B-outcome	2699	2706	Overall
I-outcome	2707	2716	mortality
O	2717	2720	was
B-iv-bin-percent	2721	2722	3
I-iv-bin-percent	2722	2723	·
I-iv-bin-percent	2723	2724	9
I-iv-bin-percent	2724	2725	%
O	2726	2727	(
O	2727	2728	2
O	2728	2729	·
O	2729	2730	7
O	2730	2731	-
O	2731	2732	5
O	2732	2733	·
O	2733	2734	8
O	2734	2735	)
O	2736	2739	for
O	2740	2746	TARGIT
O	2747	2753	versus
B-cv-bin-percent	2754	2755	5
I-cv-bin-percent	2755	2756	·
I-cv-bin-percent	2756	2757	3
I-cv-bin-percent	2757	2758	%
O	2759	2760	(
O	2760	2761	3
O	2761	2762	·
O	2762	2763	9
O	2763	2764	-
O	2764	2765	7
O	2765	2766	·
O	2766	2767	3
O	2767	2768	)
O	2769	2772	for
O	2773	2777	EBRT
O	2778	2779	(
O	2779	2780	p
O	2780	2781	=
O	2781	2782	0
O	2782	2783	·
O	2783	2786	099
O	2786	2787	)
O	2787	2788	.

O	2789	2794	Wound
O	2794	2795	-
O	2795	2802	related
O	2803	2816	complications
O	2817	2821	were
O	2822	2826	much
O	2827	2830	the
O	2831	2835	same
O	2836	2843	between
O	2844	2850	groups
O	2851	2854	but
B-outcome	2855	2860	grade
I-outcome	2861	2862	3
I-outcome	2863	2865	or
I-outcome	2866	2867	4
I-outcome	2868	2872	skin
I-outcome	2873	2886	complications
O	2887	2891	were
O	2892	2905	significantly
O	2906	2913	reduced
O	2914	2918	with
O	2919	2925	TARGIT
O	2926	2927	(
B-iv-bin-abs	2927	2931	four
O	2932	2934	of
B-intervention-participants	2935	2939	1720
O	2940	2942	vs
B-cv-bin-abs	2943	2945	13
O	2946	2948	of
B-control-participants	2949	2953	1731
O	2953	2954	,
O	2955	2956	p
O	2956	2957	=
O	2957	2958	0
O	2958	2959	·
O	2959	2962	029
O	2962	2963	)
O	2963	2964	.

O	2965	2971	TARGIT
O	2972	2982	concurrent
O	2983	2987	with
O	2988	2998	lumpectomy
O	2999	3005	within
O	3006	3007	a
O	3008	3012	risk
O	3012	3013	-
O	3013	3020	adapted
O	3021	3029	approach
O	3030	3036	should
O	3037	3039	be
O	3040	3050	considered
O	3051	3053	as
O	3054	3056	an
O	3057	3063	option
O	3064	3067	for
O	3068	3076	eligible
O	3077	3085	patients
O	3086	3090	with
O	3091	3097	breast
O	3098	3104	cancer
O	3105	3114	carefully
O	3115	3123	selected
O	3124	3126	as
O	3127	3130	per
O	3131	3134	the
O	3135	3141	TARGIT
O	3141	3142	-
O	3142	3143	A
O	3144	3149	trial
O	3150	3158	protocol
O	3158	3159	,
O	3160	3162	as
O	3163	3165	an
O	3166	3177	alternative
O	3178	3180	to
O	3181	3194	postoperative
O	3195	3199	EBRT
O	3199	3200	.

O	3201	3211	University
O	3212	3219	College
O	3220	3226	London
O	3227	3236	Hospitals
O	3237	3238	(
O	3238	3242	UCLH
O	3242	3243	)
O	3243	3244	/
O	3244	3247	UCL
O	3248	3261	Comprehensive
O	3262	3272	Biomedical
O	3273	3281	Research
O	3282	3288	Centre
O	3288	3289	,
O	3290	3294	UCLH
O	3295	3304	Charities
O	3304	3305	,
O	3306	3314	National
O	3315	3324	Institute
O	3325	3328	for
O	3329	3335	Health
O	3336	3344	Research
O	3345	3351	Health
O	3352	3362	Technology
O	3363	3373	Assessment
O	3374	3383	programme
O	3383	3384	,
O	3385	3394	Ninewells
O	3395	3401	Cancer
O	3402	3410	Campaign
O	3410	3411	,
O	3412	3420	National
O	3421	3427	Health
O	3428	3431	and
O	3432	3439	Medical
O	3440	3448	Research
O	3449	3456	Council
O	3456	3457	,
O	3458	3461	and
O	3462	3468	German
O	3469	3476	Federal
O	3477	3485	Ministry
O	3486	3488	of
O	3489	3498	Education
O	3499	3502	and
O	3503	3511	Research
O	3511	3512	.
